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Abstract
Background: Growing evidence suggests that experiences in the early years play a major role in children’s
development in terms of health, wellbeing and educational attainment. The Trial of healthy relationship initiatives
for the very early years (THRIVE) aims to evaluate two antenatal group interventions, Enhanced Triple P for Baby and
Mellow Bumps, designed for those with additional health or social care needs in pregnancy. As both interventions
aim to improve maternal mental health and parenting skills, we hypothesise that in the longer term, participation
may lead to an improvement in children’s life trajectories.
Methods: THRIVE is a three-arm, longitudinal, randomised controlled trial aiming to recruit 500 pregnant women
with additional health or social care needs. Participants will be referred by health and social care professionals,
predominately midwives. Consenting participants will be block randomised to one of the three arms: Enhanced
Triple P for Baby plus care as usual, Mellow Bumps plus care as usual or care as usual. Groups will commence when
participants are between 20 and 34 weeks pregnant.
Discussion: The population we aim to recruit are traditionally referred to as “hard to reach”, therefore we will
monitor referrals received from maternity and social care pathways and will be open to innovation to boost referral
rates. We will set geographically acceptable group locations for participants, to limit challenges we foresee for group
participation and retention. We anticipate the results of the trial will help inform policy and practice in supporting
women with additional health and social care needs during antenatal and early postnatal periods. This is currently a
high priority for the Scottish and UK Governments.
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Background
Emerging neuroscience evidence suggests that the interac-
tions between a child and their mother, particularly from
conception to age 3 years, greatly influence the develop-
ment of the child’s “base for competence and coping skills
that will affect learning, behaviour and health throughout
life” [1]. Women with additional health and social care
needs in pregnancy (for instance, due to domestic abuse,
mental health problems, an addiction, having been in state
care, etc.) are likely to be more anxious, depressed and
have higher levels of circulating stress-related hormones
[2], which can (1) create adverse epigenetic modifications
to the developing foetus that permanently affect the baby’s
response to stress [3, 4] and (2) independently disrupt the
mother’s ability to be sensitive to her baby [5]. Both these
pathways may adversely affect the mother-infant inter-
action. In addition, both poor mother-infant interaction
and maternal mental ill health strongly predict child
maltreatment [6, 7] and a disadvantaged trajectory for
children in terms of their future social, emotional and cog-
nitive development and health [8–10]. Thus, postnatal
interventions may not be able to undo all of the changes
resulting from maladaptive coping in adverse circum-
stances during pregnancy.
Sensitive mother-infant interactions are characterised by
reciprocal communication from an early stage, which fa-
cilitates language but also significantly reduces the risks of
maltreatment. This is thought to be due to mothers per-
ceiving their infants as co-operating with them [11].
Mother-infant interactions that succeed in facilitating
secure future attachments enable overall development,
including language, and may set infants onto a more posi-
tive life trajectory. The evidence for the effect of early
child development on health and wellbeing in later life is
widely accepted and early childhood interventions, such as
the High/Scope Perry Preschool Project [12], the USA
Family Nurse Partnership (FNP) [13], the Carolina
Abecedarian Project [14] and the Chicago Child-Parent
Programme [15], have had positive effects on a number of
child development domains and on wellbeing and life
success in adulthood. Furthermore, early intervention, is
generally more cost-effective than intervening later, and is
most effective in the antenatal period [16]. However, many
applied economic evaluations in the area of home visiting
and parenting have had diverse economic objectives and
methodological problems including the lack of a societal
perspective and limited cost analysis.
We hypothesise that the provision of a parenting support
intervention, Enhanced Triple P for Baby (ETPB) orMellow
Bumps (MB), in addition to routinely provided care during
the antenatal and early postnatal phase, will be a cost-ef-
fective way of improving maternal mental health, increasing
the dyadic synchronicity and sensitivity of mother-infant
interactions, reducing the risk of child maltreatment and
improving child language and socio-emotional develop-
ment. The Trial of healthy relationship initiatives for the
very early years (THRIVE) is a three-arm, randomised
controlled trial of women with additional health and social
care needs in pregnancy aiming to compare ETPB plus
care-as-usual (CAU) or MB plus CAU with CAU. Based on
recent economic evaluation research carried out on a simi-
lar trial in Oxfordshire [17, 18], THRIVE will include a
comprehensive economic evaluation.
The primary research questions that will be addressed
by THRIVE are:
1. Do participants receiving ETPB plus CAU or MB
plus CAU have significantly lower anxiety,
depression and outwardly directed irritability
compared with those receiving CAU alone when
their infants are around 6 months old?
2. Do participants who receive ETPB plus CAU or
MB plus CAU have more sensitive interactions with
their infants compared with those receiving CAU
alone when their infants are around 6 months old?
The secondary research questions that will be addressed
by THRIVE are:
1. Do infants whose parent(s) receive ETPB plus CAU or
MB plus CAU show more cooperative behaviour signs
than those whose parent(s) received CAU alone?
2. Do ETPB or MB lead to changes in the number of
children flagged as “at risk” on the social services
risk register, under a child protection plan, taken
into local authority care or attending an accident
and emergency department?
3. Do ETPB or MB lead to improvements in the
socio-emotional development of children around
30months old?
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4. Do ETPB or MB lead to an improvement in language
development in children around 30months old?
5. Do ETPB or MB lead to an improvement in longer-
term educational and health outcomes for children?
6. Is either ETPB or MB cost-effective for the
National Health Service (NHS) or society more
broadly, in the long term?
7. Do differences in programme fidelity, practitioners’
characteristics and motivation, mothers’
engagement, the intervention mechanisms and
contextual factors affect mother and infant
outcomes?
8. Does fathers’ involvement or support affect
mothers’ engagement with ETPB or MB?
9. How do participants’ experiences of being parented
influence their own parenting values and behaviour?
Methods
THRIVE is a three-arm, randomised controlled trial of
500 participants with additional health and social care
needs in pregnancy, classified by National Health Service
Greater Glasgow & Clyde (NHS GGC) Special Needs in
Pregnancy service (SNiPs) protocol [19] (e.g., domestic
violence, mental illness, a history of substance misuse, be-
ing looked after in local authority care or criminal justice
involvement). Consenting participants will be randomly
allocated to one of the three trial arms: ETPB plus CAU,
MB plus CAU or CAU alone. All participants and their
infants will continue to receive their antenatal and postna-
tal CAU according to local NHS and local authority
guidelines.
THRIVE is sponsored by NHS GGC Health Board
(Reference GN12KH589; NHS Greater Glasgow & Clyde,
Research and Development Management Office, West
Glasgow Ambulatory Care Hospital, Dalnair Street, Glas-
gow), which is responsible for ensuring that THRIVE is
managed “according to the Research Governance Frame-
work for Health and Community Care (Second edition,
2006) and World Medical Association Declaration of
Helsinki Ethical Principles for Medical Research Involving
Human Subjects”. The study is subject to audit by the
NHS GGC Health Board at any time during the trial. In
addition, the University of Glasgow Medical Research
Council/Chief Scientist Office Social and Public Health
Science Unit (MRC/CSO SPHSU) has standard operating
procedures that include auditing of ongoing studies.
Inclusion criteria
Pregnant women aged 16 years and older (or 14 years and
older with social work support) who meet the SNiPs cri-
teria, have capacity to consent and are living within the
geographical areas of NHS GGC and NHS Ayrshire &
Arran (NHS A&A) will be invited to take part in THRIVE
when they are between 8 and 24weeks pregnant. The trial
team will use a variety of methods to maximise participant
recruitment into the trial:
1. Patients within NHS GGC will be routinely asked if
their information can be passed onto researchers. If
a pregnant women assents, a THRIVE researcher
will contact her to discuss the trial, screen for
eligibility and seek consent to recruit to the trial.
2. Participants will be referred by their health or social
care practitioner(s) to the research team.
3. Members of the THRIVE team will attend antenatal
clinics in hospital and community settings to meet
with pregnant women. Participants will be screened
by researchers for eligibility.
4. Targeted advertisements, including web-based
content, will be used to recruit participants via
community centres, health centres, local classified
sites, social media and parenting forums. Interested
parties will be screened for eligibility by members of
the research team.
Following informed, written consent to participate in
the trial (Additional file 1), participants will be asked to
complete baseline measures after a viable pregnancy has
been confirmed through medical records, around the
12th week of pregnancy.
Exclusion criteria
The following participants will be excluded from the
trial:
1. Women with difficulties in speaking or
comprehending English, because this can limit their
ability to engage in group sessions.
2. Women with no fixed abode, because it may be
difficult to trace and retain them within a
longitudinal study.
3. Women experiencing active psychosis, because this
illness can limit their ability to engage in group
sessions.
4. Women for whom it is known during pregnancy
that their child will be removed at birth, because
doing so may make the separation more difficult.
Advice about the suitability of potential participants to
participate in the trial will be sought from the referring
health or social care practitioners.
Interventions
Enhanced Triple P for Baby (ETPB)
ETPB, informed by social learning theory, is an interven-
tion designed to facilitate a smooth transition to parent-
hood for expectant parents by reducing the impact of
known risk factors for perinatal distress and difficulties.
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It aims to provide infants with a healthy start to life by
offering parenting skills training as well as psychological
coping skills training to parents to enhance parental and
infant wellbeing. In addition to focusing on practical
parenting and coping skills, group sessions encourage
participants to work with their partner or a supportive
individual to develop and explore strategies needed to
maintain more harmonious family relationships. Each
participant’s partner or supportive other is invited to all
of the group sessions but participants without support
are not excluded. The programme offers four 2-h ante-
natal group sessions in a community setting and up to
three individual 1-h postnatal sessions delivered face-to-
face in the woman’s home. The programme is completed
with a final 2-h postnatal group session. Antenatal ses-
sions are scheduled to begin before the woman is 34
weeks pregnant, and the postnatal sessions are delivered
after their infant is 6 weeks old. ETPB was developed at
the Parenting and Family Support Center at the University
of Queensland, Australia. Triple P interventions, provided
by Triple P International (http://www.triplep.net), are
delivered to parents in five different levels of intensity, the
efficacy and effectiveness of which have been cited in
numerous studies and randomised trials [20, 21]. More re-
cently, however, there has been a call for more registered
independent trials (with pre-specified main outcomes),
such as THRIVE [22].
Mellow Bumps (MB)
MB is underpinned by attachment theory and aims to
encourage nurturing and attuned relationships between
the mother and developing infant. MB is intended to de-
crease maternal antenatal stress levels, increase expect-
ant mothers’ understanding of the neonates’ capacity for
social interaction and emphasise the importance of early
interaction in enhancing brain development and attach-
ment. Participants are encouraged to identify potential
sources of stress and work through how to manage
these, reflect upon and identify sources of positive social
support and to identify barriers to good parenting. The
programme offers seven 2-h antenatal group sessions
and one 2-h postnatal group session. Antenatal sessions
begin when participants are between 20 and 30 weeks
pregnant, and the postnatal sessions are delivered when
infants are between 6 and 12 weeks old. Partners and/or
supportive others are invited to attend one antenatal ses-
sion. MB was developed by a charity, Mellow Parenting
(http://mellowparenting.org), based in Govan, Glasgow.
Evidence for Mellow Parenting programmes is small-
scale but encouraging [23–25].
Care-as-usual (CAU)
All participants in this study will continue to receive
their routine antenatal and postnatal care. Generally, this
involves care from hospital and community-based health-
care specialists, such as midwives, obstetricians and health
visitors. The exact care received by each participant will
depend on their individual additional health and social
care needs and may also engage services from other
sources including social work services and voluntary agen-
cies. All care received will be in line with local authority
and Government policy and guidelines [19, 26–30]. The
specific services accessed by each participant as part of
their CAU will be captured in service use diaries.
Participants randomised to the CAU arm of the trial
will not be offered either intervention (ETPB or MB) in
THRIVE on completion of data collection. However,
participants may access Triple P International and Mel-
low Parenting programs as part of their CAU, where
these are offered through social work or third-sector or-
ganisations within NHS GGC and NHS A&A. Uptake of
other parenting programmes outside of THRIVE will be
captured in the service use diary.
Trial group organisation
Post randomisation the group sessions will be organised
by administrative staff within the trial research team and
delivered in community settings, such as local supermar-
ket community rooms or hospital antenatal education
rooms. A taxi service will be provided, first, to ensure
safe transport of participants to and from the group
venue sessions and second, with the aim of reducing an-
ticipated transportation barriers and thereby supporting
attendance. The trial administrator will contact partici-
pants by phone or text to invite them to sessions, with
reminders sent on the day of each group session to
maximise group attendance. Attendance at each session
will be recorded in an attendance register by group
facilitators.
Participation in all aspects of THRIVE will be volun-
tary, and some participants may choose not to attend
any or to attend only some of the group sessions. In
these situations, the research team will seek to record
the reason for non-attendance. For MB, participants
who do not attend either of the first two group sessions
will not be invited to subsequent sessions, but will still
be eligible for follow-up data collection. For ETPB, par-
ticipants will be invited to all antenatal group sessions
regardless of attendance at previous sessions.
THRIVE group facilitators will be independent of the
trial, have a variety of health and social care professional
backgrounds, and be employed by NHS GGC and NHS
A&A. In order to avoid contamination between inter-
vention arms in the trial group, facilitators will be ran-
domly allocated to deliver only one intervention, the
only exception being those with prior knowledge of an
intervention - in this instance they will be allocated to
deliver that intervention. Training will be conducted by
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qualified trainers from the host organisation of each
intervention.
Outcome evaluation
Data will be collected at two time points as outlined
subsequently.
Baseline: 12–24 weeks pregnant
The baseline questionnaire (Additional file 2) will include
the following validated measures:
1. The Brief Symptom Inventory (BSI-53; Question
(Q)48 (Additional file 2)), which is a 53-item
questionnaire covering nine symptom dimensions:
somatization, obsession-compulsion, interpersonal
sensitivity, depression, anxiety, hostility, phobic
anxiety, paranoid ideation and psychoticism [31, 32].
The Global Severity Index from this scale will be used
in randomisation to indicate severity of symptoms.
2. The Hospital Anxiety and Depression Scale
(HADS), which is a 14-item questionnaire assessing
symptoms of anxiety and depression [33]. This will
be enhanced by the 4-item outwardly directed
irritability (I) questions adopted from the Adult
Wellbeing Scale (AWS) [34], as a baseline measure
for the primary outcome of maternal mental
wellbeing (Q47).
3. The EuroQol 5 Dimensions (EQ-5D-3 L; Q49),
which is a standardized instrument to measure
health-related quality of life, which will be used for
health economic analyses [35].
4. The 23-item Recent Life Events questionnaire
(Q45), to determine the experience of specific
events in the past year, and whether these affect the
respondent [36, 37].
5. The 12-item attitudes and pregnancy to the baby
subscale from the Maternal Attitudes and Maternal
Adjustment questionnaire (Q32) [38].
6. The 28-item Childhood Trauma Questionnaire (Q89)
as a measure of childhood abuse and neglect [39].
The baseline questionnaire will also include questions
assessing reasons for vulnerability in pregnancy; socio-
demographic characteristics including age, Scottish Index
of Multiple Deprivation, ethnicity, education and employ-
ment; previous childbirth history and parity; health in
pregnancy; and substance abuse [40].
Follow up at 6 months postnatal (primary outcome end
point)
The primary outcome of maternal mental wellbeing will
be assessed by the HADS+I, included in the follow-up
questionnaire (Additional file 3; Q35). The primary out-
come of mother-infant interaction quality (MIIQ) will be
measured based on the CARE Index Dyadic Synchrony
Score [41] determined from an episode of play recorded
during the follow-up visit when the infant is around 6
months old.
In addition to the HADS+I, the follow-up question-
naire will include the following listed validated measures
that will be analysed as secondary outcome measures:
1. The 33-item Support and Control in Childbirth
Scale will be used to determine the participants
experiences during childbirth (Q14) [42].
2. The EQ-5D-3 L will be used within health
economics analyses (Q36) [35].
3. The 23-item Recent Life Events questionnaire
(Q41) will be used to determine the experience of
specific events in the past year, and whether these
affect the respondent [36, 37].
4. The 18-item Cognitive Emotion Regulation
questionnaire (Q42) will be used to determine
cognitive emotion regulation across nine conceptual
scales: self-blame, other-blame, rumination,
catastrophizing, positive refocusing, planned,
positive reappraisal, putting into perspective and
acceptance [43].
5. The 18-item partner subscale of the Postpartum
Support Scale (Q68) [44] will be used.
6. The 18-item Parental Regulation Inventory will
assess the degree to which parents use specific
strategies to encourage or discourage their partner
to be involved in parenting (Q69) [45].
7. The 12-item marital relationship scale of the
Maternal Adjustment and Maternal Attitudes
questionnaire (Q70) will be used [38].
8. The 12-item Multidimensional Scale of Perceived
Social Support relating to support from a significant
other, family and friends will be used (Q87) [46].
9. The 15-item Karitane Parenting Confidence Scale
will be used to assess parenting self-efficacy
(Q88) [47].
10. The 14-item Maternal Attitudes Questionnaire will
be used to assess attitudes towards motherhood
across three domains: expectations of motherhood,
expectation of self as a mother and role conflict
(Q89) [48].
11. The Parent Coping Scale, a single question will be
used to provide a global measure of coping with
being a parent (Q92) [49].
12. The 43-item Infant Crying Questionnaire will be
used to assess participants’ thoughts/feeling towards
infant crying and how they would respond (Q93
and Q94) [50].
13. We will use 16 items from the Postpartum Bonding
questionnaire to assess the quality of the mother’s
relationship with her baby (Q96) [51].
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During the follow-up visit permission will be sought to
video-record mother and child interactions around one
episode of play and one episode of care, such as feeding
or nappy changing. MIIQ will be rated by two research
assistants at The University of Manchester (UoM) who
will be blinded to the trial arm allocation ensuring sin-
gle-blind evidence of the effectiveness of the interven-
tions on MIIQ. MIIQ will be measured using both the
CARE Index Dyadic Synchrony Score (primary end-
point) [41] and the Mellow Parenting Observation
System (MPOS) [52]. As part of this process inter-rater
reliability will be established.
As the target population of this study is traditionally
seen as “hard to reach”, a number of strategies will be
undertaken in order to obtain follow-up data from as
many participants as possible, including the offer of £15
vouchers for completed follow-up questionnaires, con-
tact by phone, email and text to arrange follow-up data
collection appointments, confirmation of current contact
details with the NHS Clinical Research Facility and send-
ing out congratulations cards at birth with a reminder to
inform research staff of changes in contact details.
Economic Evaluation
The economic evaluation will assess the implementation
costs, resource use and outcomes associated with each
intervention and CAU from the NHS and Personal So-
cial Services (PSS) perspective favoured by the National
Institute for Health and Care Excellence (NICE). A
broader societal perspective will also be adopted to allow
for the possibility of costs and outcomes arising beyond
the NHS and PSS, such as housing, education, employ-
ment and justice. To facilitate measurement of data on
resource use, all participants will be asked to keep a ser-
vice use diary recording attendance at NHS, social care,
local authority and voluntary organisations for both
mother and child. The diary will be used as an aide
memoir to collect mother and child data between base-
line and follow up, and will be used to measure add-
itional and unintentional cost burden/savings associated
with the intervention. Participants will additionally be
asked to complete a health and social care resource-use
questionnaire at follow up based on the same informa-
tion as the diary.
Up-to-date unit costs will be attached to quantities of
resource use to generate mean costs per study participant.
The incremental costs and benefits of the treatment arms
compared with CAU will be reported within an incremen-
tal cost-effectiveness ratio (ICER) if appropriate. The
inclusion of the EQ-5D generic outcome measure [35] will
also allow the estimation of quality-adjusted life years
(QALYs) facilitating cost-utility analysis, the preferred
evaluative technique of NICE. Sensitivity analysis will be
carried out on the perspective adopted and the key cost-
drivers and outcomes. As per recent economic evaluation
guidance, missing data will be predicted as a function of
relevant baseline covariates [53].
Process evaluation
Embedded within THRIVE is a realist process evaluation
which will carefully monitor what is happening within
the trial. Realistic evaluation [54] will provide the theor-
etical rationale for the process evaluation, which will
seek to answer the following questions:
1. How faithfully are ETPB and MB implemented?
2. What are the mechanisms by which they work, if
they do, who do they work for and how?
3. What contextual factors are necessary for the
programmes to function, or might prevent them
from functioning?
The mixed-methods design will include:
1. Pre-training and post-training/intervention
questionnaires for practitioners and mothers to be
and post-session evaluation forms.
2. Participant observation of practitioner training and
the delivery of a series of antenatal sessions.
3. Semi-structured interviews with practitioners,
mothers to be, partners and referring practitioners.
4. Telephone interviews with mothers examining the
content of the postnatal components of ETPB and
MB.
The findings will aid interpretation of the outcomes of
THRIVE by providing a greater understanding of how the
interventions work (if they do), the extent and quality of
their implementation, contextual factors facilitating and
constraining intervention functioning, variations in re-
sponse within and between subgroups of vulnerable par-
ents and benefits or unintended consequences of either
intervention. For further information, please consult [55].
A timeline of activities for participants in each arm of
the trial is shown in Fig. 1 and a schedule of study activ-
ities is shown in a SPIRIT diagram (Fig. 2). A Standard
protocol items: recommendation for interventional trials
(SPIRIT) checklist indicating where standard protocol
items for randomised controlled trials are located within
this protocol is included in Additional file 4.
Planned longer-term follow up using routine data (still to
be funded)
Longer-term outcomes will be assessed by linking the
short-term outcomes identified in the study to longer-
term impacts on health and wellbeing for both mother
and child via factors identified from the literature. This
trial aspect will rely on linking published associative data
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and any short-term primary outcomes identified in the
trial with long-term costs and benefits in health and
education, and other effects such as the effect on em-
ployment. Routine data, such as the Strengths and Diffi-
culties Questionnaire, [56] collected by health and social
care professionals when the child is around 30months
old, will facilitate the measurement of longer-term
outcomes including social and emotional wellbeing, lan-
guage development, educational attainment, incidences
of maltreatment or neglect and placement of children
onto the “risk register”/into child protection services. Fu-
ture linkage will also assess the costs of health, social
care and broader education and employment impacts. In
addition, it will provide important information in terms
of health status and the use of services across the study
groups.
All data linkage will be initiated by the Robertson
Centre for Biostatistics, which is a registered Clinical
Trials Unit (CTU), using the NHS GGC’s Safe Haven
that has been developed to support secondary research
use of clinical data. Data from NHS A&A will also be re-
quired and access to these data via Safe Haven should
become available during the life of THRIVE. If this does
not occur, then the research team will seek permission
from the NHS Information Services Division (ISD
Scotland) to link NHS records for NHS A&A’s patients
into the Safe Haven.
The research team understands that data linkage at
the individual level is sensitive and raises issues of priv-
acy, and will ensure that all data linkage undertaken ad-
heres to the standards outlined by ISD Scotland [57]. In
addition, the NHS GGC’s Safe Haven is subject to a local
privacy advisory committee that will ensure that that
risks to privacy at the individual patient level are
minimised.
Randomisation
Participants will be allocated a unique identification (ID)
number by the research team on entry to the study. This
ID number will be used to anonymise completed baseline
questionnaires, which will be delivered to the CTU for
data entry. The CTU will block-randomise participants to
the three trial arms using a computer-generated sequence,
stratified by parity (number of children), severity of psy-
chiatric symptoms (measured by the BSI, 53) and history
of substance dependency, which will be determined based
Fig. 1 Timeline of participant activities. HADS+1, Hospital Anxiety and Depression Scale enhanced by the outwardly-directed irritability questions
adopted from the Adult Wellbeing Scale; EQ-5D, EuroQol 5 Dimensions - a standardised instrument used as a generic measure of health; SNiPs,
Special needs in pregnancy; CAU, care as usual; ETPB, Enhanced Triple P for Baby; MB, Mellow Bumps
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on baseline questionnaire responses. For every 12 partic-
ipants randomised, two will receive CAU, five will be
offered ETPB and five will be offered MB. The re-
search team will receive details of each participant’s
intervention arm allocation by email from the CTU
based on their ID number. The research team will
then contact the participant to let them know which
trial arm they have been allocated and to provide de-
tails of the group session for those allocated to ETPB
or MB. Where consent is provided, the research team
will also send a letter to the participant’s health and
social care providers to let them know the interven-
tion arm allocation.
Blinding
Researchers at the MRC/CSO SPHSU, University of
Glasgow (UoG) and at Glasgow Caledonian University
(GCU) will not be blinded to trial arm allocation due to
their direct contact with participants. CTU statisticians
and data processers will only receive anonymised data
and will not have direct contact with participants. Re-
searchers at UoM will be blinded to trial arm allocation,
Fig. 2 Standard protocol items: recommendation for interventional trials (SPIRIT) diagram indicating the schedule of THRIVE study activities. GP,
General Practitioner; EQ-5D-3L, EuroQol 5 Dimensions, 3 Levels - a standardised instrument used as a generic measure of health; CAU, care as
usual; ETPB, Enhanced Triple P for Baby; MB, Mellow Bumps; NHS, National Health Service; A&E, Accident and Emergency
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providing a single-blind evaluation of the quality of
mother-infant interactions.
Storage and anonymisation of confidential data
All data collected will be stored securely, in accordance
with the UoG Best Research Practice Guidelines, and
managed in accordance with the Data Protection Act
1998 and the General Data Protection Regulation (from
May 2018), in either locked filing cabinets or password-
protected databases. Data will be accessible only by
members of the UoG research team and their research
partners at GCU, UoM and the Universities of Aberdeen
and Newcastle. All of the data collected will be kept
separate from any individual participant identifiers and
secure. Participants will be given their own unique ID
number in order to link their data throughout the trial.
All quantitative data collected as part of the study will
be securely transferred to the Robertson Centre for Bio-
statistics CTU for data entry and cleaning.
Qualitative interview data and recordings of interven-
tion delivery sessions will be transcribed by an external
(security checked) transcription agency, and securely
stored by researchers based at the UoG and GCU.
Video-recordings of mother-infant interactions will be
transferred to the UoM using a secure Internet platform
designed and maintained by the Robertson Centre for
Biostatistics for observer-rated coding using the CARE
Index and the MPOS. The one exception to this rule is
to allow the secure transfer of a small number of an-
onymous video-recordings to Mellow Parenting for rater
quality-control checks.
In all cases data sharing and confidentiality agreements
will be line with the UoG regulations. Permission will be
sought from participants for archiving purposes during
trial consent, and the trial consent form will notify partici-
pants that their data and their child’s data will be made
available to the funders in anonymised form.
Statistical analysis
THRIVE has been powered based on the primary out-
come measure of maternal mental wellbeing. The effi-
cacy of ETPB and MB will be analysed at a significance
level of 2.5% in order to maintain an overall type I error
rate of 5%. Two analyses, performed in a hierarchical
fashion so that no further p value adjustment is neces-
sary, will be undertaken. In analysis 1, the combined
intervention groups (ETPB and MB) will be compared
with CAU. If analysis 1 detects a difference at a 2.5%
level of statistical significance, analysis 2 will compare
ETPB with MB as a primary analysis, to be judged at a
2.5% statistical significance level. If analysis 1 does not
yield a statistically significant result, then analysis 2 will
be considered a secondary analysis.
Power calculation
In order to have 90% power to detect an effect size of 0.4
for Analysis 2 (ETPB versus MB) 157 participants are
required in both the ETPB plus CAU and MB plus CAU
groups. Comparing these 314 participants with CAU alone
in analysis 1 (ETPB and MB vs CAU), requires 61 partici-
pants in the CAU alone group to achieve 90% power.
Therefore, 375 participants are required in a ratio of
ETPB:MB:CAU of approximately 5:5:2. To allow for 25%
attrition at follow up, 500 participants will be recruited
and randomised.
Planned analysis
Baseline-adjusted linear regression analysis (analysis of
covariance) will be used to compare primary statistical
outcomes between intervention groups. Similar methods
will be used for other outcomes (using data transform-
ation and alternative regression methods, depending on
the distribution of each outcome). Regression models
will be extended to investigate the effects of baseline
characteristics and the potential moderating effects of
these variables and other measures of intervention com-
pliance. Repeated measures methods will be applied to
outcomes collected at more than one post-baseline
assessment.
For participants discontinuing from the study before
the postnatal follow-up data collection, baseline data will
continue to be analysed when consent is provided. Miss-
ing values will not be imputed. The sensitivity of the pri-
mary outcome analysis to missing values will be explored
using multiple imputation, generating 10 imputed data
sets, using all available data to predict missing values.
Analyses will be conducted for the intention-to-treat
population, consisting of all participants who have
been randomised to the trial. In addition, analyses
will also be undertaken for the per-protocol/on-treat-
ment population.
For the economic analysis the incremental costs and
benefits in each treatment arm will be reported
within an incremental cost-effectiveness ratio (ICER)
if appropriate. Within-trial analysis of costs and ef-
fects will be undertaken in STATA (StataCorp, TX,
USA), adhering to good practice for economic evalua-
tions alongside clinical trials [58, 59]. Missing data
will be explored by employing multiple imputation
methods using alternative configurations of baseline
covariates [53, 60]. Based on the availability of linked
routine data, longer-term costs and outcomes will be
assessed by linking short-term outcomes identified in
the study to potential longer-term impacts on health
and wellbeing for both mother and infant, via trial
extrapolation methods including economic modelling
techniques.
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Monitoring
Data Monitoring Committee (DMC)
The DMC, chaired by Professor John Norrie (j.norrie@ed.
ac.uk), will meet regularly (as required) to assess trial pro-
gress based on independent trial data (e.g., actual recruit-
ment to trial against projected trial recruitment), provided
by the Robertson Centre for Biostatistics CTU and will be
given the power to stop the trial should the committee see
fit.
If analysis of follow-up data shows that maternal psy-
chological distress significantly worsens after participation
in either intervention, we shall seek guidance from the
Trial Steering Committee (TSC) and DMC about how to
respond, as by that time all of the participants allocated to
the ETPB and MB arms will have already received an
intervention.
Trial Steering Committee
THRIVE will be supported by a TSC comprising aca-
demic and health professionals, all of whom are special-
ists in early years and/or maternal mental health. The
TSC will also have a lay member. The committee will be
chaired by Professor Rudi Dallos, Plymouth University
(R.Dallos@plymouth.ac.uk). It will meet once or twice a
year (as required) to provide advice to the research team.
Exceptional meetings can be called by the Chair or the
Chief Investigator (CI) if guidance is sought as a matter
of urgency. Publication plans will be discussed in full
with the TSC.
Potential harms
a) Data collection
THRIVE will adhere to Good Clinical Practice guide-
lines on safety reporting in clinical trials. Our quantita-
tive data collection procedure will consist of completing
repeat questionnaires with trained researchers (including
Good Clinical Practice training), all of whom will have
undergone criminal background checks and have signifi-
cant experience of working with vulnerable groups.
Whilst the questionnaire consists of well-established
measures that are not known to be problematic, it is
possible that participants may become upset whilst com-
pleting the questionnaires. All researchers will receive
training in how to handle participant distress and will
follow NHS guidance relating to patient confidentiality
and protection, including vulnerable adult and child pro-
tection procedures. A “useful contacts” sheet will be
given to all participants to signpost them to relevant ser-
vice providers.
Should a researcher become concerned about a par-
ticipant, s/he will raise this concern with relevant health
and/or social care professionals to ensure the participant
receives the adequate care they require. In this situation,
researchers will complete an incident report form outlin-
ing the steps taken and a decision will be made by the
CI, Project Manager (PM) and Sponsor as to whether
the incident should be reported as an adverse event. The
same risks are present in conducting qualitative inter-
views with participants. All interviewers will have experi-
ence in conducting qualitative interviews and working
with vulnerable populations and will follow the afore-
mentioned procedures if participant distress is evident.
While researchers may signpost participants to further
support services, or, with the participant’s consent, con-
tact their health or social care providers to initiate on-
going support, no formal ongoing post-trial support will
be offered by the research team themselves.
b) Participation in the interventions
We will be working with vulnerable women at a sensi-
tive period in their lives, and some activities, such as
being asked to reflect upon past experiences, may have
the potential to cause distress: however, other research
suggests asking about adverse childhood events does not
cause measurable distress [61]. Furthermore, we believe
that this risk is minimal because both interventions are
designed to reduce stress through positive action and
the development of coping strategies. In addition, the
group facilitators will undergo training to work with this
group of women and will be able to provide empathetic
support and signpost participants to services should they
require additional support. The group dynamics may
help to reduce stress/distress to participants by provid-
ing a supportive and considerate atmosphere in which
issues can be discussed. However, it must be recognised
that the delivery of ETPB and MB within group settings
carries a risk that participants might choose to discuss
issues raised with others outside of the group setting. As
the focus of the group sessions is more on activities and
active discussion rather than disclosing personal histor-
ies, the risk of this occurring is low. Nevertheless, to
promote respect and confidentiality amongst partici-
pants the intervention facilitators will work with them to
establish group rules about confidentiality, especially in
relation to social media. Furthermore, the bringing to-
gether of vulnerable participants may result in the for-
mation of positive or negative group interactions and
social networks. Group facilitators will be given the
adequate support and resources necessary to signpost
participants to appropriate services. At all times, groups
facilitators will adhere to NHS guidance relating to
patient confidentiality and protection, including vulner-
able adult and child protection procedures, and report
any concerns about participants to both the PM and
their line manager at the NHS GGC Clinical Research
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Facility; the CI will also be kept informed and be able to
influence decision-making.
Should a participant have any concerns about their
participation in THRIVE they will be advised to contact
the trial PM, CI or the University of Glasgow, Institute
of Health and Wellbeing Research Support Manager.
These contact details will be included in the trial infor-
mation booklet given to each participant before they
consent to participate in the trial.
a) Withdrawal from the interventions or trial
Participants may choose to withdraw from the inter-
vention group or the trial at any point. Participants will
be asked a reason for withdrawal, but will not be re-
quired to respond. Participants who withdraw from the
intervention but not the trial will still be eligible for fol-
low-up data collection.
Any women that report experiencing harm from at-
tending the group will be given the support discussed
previously and advised by the research team to stop at-
tending the groups. Participants may also be advised by
their health or social care practitioner to stop attending
groups or withdraw from the trial, based on ongoing
health or social care needs. Any participant found to be
inflicting harm on another participant or group facilita-
tor will be asked to leave the group sessions and will be
withdrawn from further data collection.
It will not be appropriate for participants who no lon-
ger meet the study eligibility criteria due to intrauterine
death or stillbirth to be invited to subsequent group ses-
sions, and no further intervention or follow-up assess-
ment will be offered to these participants. Women who
give birth prematurely while the antenatal sessions of
each intervention are ongoing will no longer be eligible
to attend antenatal elements of the group but will be
offered the postnatal sessions.
Safety reporting
The research team will ask permission from participants
to notify their General Practitioner (GP) and/or other
relevant health and social care workers of her participa-
tion in the research. All participants will be told during
the consent process that if a significant risk of harm to
themselves or their baby/child(ren) is identified, the
research team will notify their GP and/or other relevant
health and social care professional(s). As previously
discussed, structures are in place for group practitioners
and researchers to follow should incidents occur relating
to the safety of participants and/or their children. When
there is a health risk or medical emergency, procedures
will be followed including alerting emergency services,
GPs or social work services as appropriate. Incidents of
this nature, or serious adverse events (SAEs), will always
be reported to the PM who will inform the CI.
Recording and reporting of adverse events
Any SAE (Table 1) occurring to a research participant
will be reported to the NHS West of Scotland Research
Ethics Committee (REC), which gave a favourable opin-
ion on the study, when in the opinion of the CI the
event was:
1. Related - that is it resulted from administration of
any research procedures, and
2. Unexpected - that is the type of event is not an
expected occurrence.
Reports of related and unexpected SAEs will be sub-
mitted to the REC within 15 days of the CI becoming
aware of the event, using the report of SAE form for
non-Clinical Trial of an Investigational Medicinal Prod-
uct (non-CTIMPS) published on the National Research
Ethics Service (NRES) website (https://www.hra.nhs.uk/
approvals-amendments/managing-your-approval/safety-
reporting/).
Annual safety reporting
The CI is also responsible for providing an annual
progress report to the REC using an NRES ‘Annual
Table 1 Definition of serious adverse events
Any adverse event or adverse reaction that:
a. Results in death
b. Is life threatening
c. Requires hospitalisation or prolongation of existing hospitalisation
d. Results in persistent or significant disability or incapacity
e. Consists of a congenital anomaly or birth defect
f. Is otherwise considered medically significant by the investigator
g. Is important but is not immediately life threatening or does not
result in death or hospitalization, but may jeopardise the subject or
may require intervention to prevent one of the other outcomes listed
in the definitions above
Table 2 Summary of protocol versions and dates
Protocol version Date
V3.0 31/10/2017
V2.1 22/04/2016
V2.0 29/10/2015
V1.5 03/12/13
V1.4 17/09/13
V1.3 10/07/13
V1.2 Internal working doc.
V1.1 Internal working doc.
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Table 3 World Health Organisation Trial Registration Data Set
Data category Information
Primary registry and trial
identifying number
ISRCTN: 21656568
Date of registration 28/02/2014
Secondary identifying numbers
Sources of monetary or material
support
National Institute of Health Research (PHR Project: 11/3002/01) Chief Scientist Office and Scottish Government
(GN12KH589 THRIVE)
Sponsor NHS Greater Glasgow and Clyde Health Board
Contact for public queries AM Alice.MacLachlan@glasgow.ac.uk
Contact for scientific queries MH Marion.Henderson@glasgow.ac.uk
Public Title THRIVE: Trial of Healthy Relationship Initiatives for the Very Early years
Scientific Title Trial of healthy relationship initiatives for the very early years (THRIVE), evaluating Enhanced Triple P for Baby and
Mellow Bumps for those with additional social and care needs during pregnancy and their infants who are at
higher risk of maltreatment: study protocol for a randomised controlled trial
Countries of recruitment Scotland
Health conditions or problem
studied
Pregnancy with additional health and/or social care needs such as mental ill health, substance abuse,
homelessness or domestic violence
Interventions Mellow Bumps Enhanced Triple P for Baby
Key inclusion criteria Pregnant, aged 16 and over with an additional health and/or social care need living in the geographical
areas of NHS Greater Glasgow and Clyde and NHS Ayrshire and Arran
Key exclusion criteria 1. Difficulties understanding written and verbal English
2. Active psychosis
3. Homelessness
4. Child will be removed at birth
Study type Longitudinal randomised control trial
Date of first enrolment 30/01/2014
Target sample size 500
Recruitment status Recruitment complete
Primary outcomes 1) Do participants receiving ETPB plus CAU or MB plus CAU show significantly lower anxiety, depression and
outwardly directed irritability compared to those receiving CAU alone when their infants are around 6months
old?
2) Do participants who receive ETPB plus CAU or MB plus CAU show more sensitive interactions with their
infants compared to those receiving CAU alone when their infants are around 6months old?
Key secondary outcomes 1) Do infants whose parent(s) receive ETPB plus CAU or MB plus CAU show more cooperative behaviour signs
than those whose parent(s) received CAU alone?
2) Do ETPB or MB lead to changes in the number of children flagged as ‘at risk’ on the social services risk
register, under a child protection plan, taken into local authority care or attending an accident and emergency
department?
3) Do ETPB or MB lead to an improvement in the socio-emotional development of children at around 30
months old?
4) Do ETPB or MB lead to an improvement in language development in children at around 30months?
5) Do ETPB or MB lead to an improvement in longer term educational and health outcomes for children?
6) Are either ETPB or MB cost-effective for the National Health Service (NHS) or society more broadly, in the
long-term?
7) Do differences in programme fidelity; practitioners’ characteristics and motivation; mothers’ engagement; the
intervention mechanisms; and contextual factors affect mother and infant outcomes?
8) Does fathers’ involvement or support affect mothers’ engagement with ETPB or MB?
9) How do participants’ experiences of being parented influence their own parenting values and behaviour?
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Progress Report form for all other research’. This form
is available at https://www.hra.nhs.uk/approvals-amend-
ments/managing-your-approval/progress-reports/.
Dissemination of data and findings
Primary results will be published in an open access peer-
reviewed journal after completion of the trial. Results will
also be made publicly available via the trial registration
(http://www.isrctn.com/ISRCTN21656568) and THRIVE
website (http://thrive.sphsu.mrc.ac.uk/). Participants are
entitled to a lay copy of a summary of the findings should
they wish.
The final anonymised data set will initially be made ac-
cessible to researchers and the public after trial comple-
tion by request to the CI, with appropriate confidentiality
agreements, with the intention to subsequently publish
the data in an online open access archive 5 years after
study completion.
Discussion
THRIVE will explore if women with additional health
and social care needs and their infants benefit from par-
ticipating in group-based antenatal and early postnatal
interventions plus CAU more than from CAU alone,
and whether these interventions are cost-effective. The
interventions are ETPB and MB (see “The interven-
tions”). In particular, we aim to investigate if the inter-
ventions in addition to CAU can improve maternal
mental health and mother-infant relationships relative to
receiving routine care alone.
The participants we aim to recruit are traditionally de-
scribed as a “hard to reach” population, and THRIVE
will be one of the largest definitive trials to date in this
population in the perinatal period. We will be monitor-
ing referrals by midwives and social care pathways and
be open to innovation to increase the number of refer-
rals and their quality (in terms of eligibility for the trial
and communication of referral criteria).
We anticipate the results of the trial will add to the lit-
erature on perinatal help and help inform policy and
practice in supporting women with additional health and
social care needs during antenatal and early postnatal
periods.
Trial status
This publication is based on protocol version 3.0, 31
October 2017. Dates for previous versions of the
THRIVE protocol are listed in Table 2. The Sponsor and
the NHS West of Scotland Research Ethics Committee
approved all protocol modifications, and all changes
were communicated to relevant parties in a timely man-
ner. Recruitment for the trial was conducted between
January 2014 and March 2018.
World Health Organisation registration
Details of the World Health Organisation registration
data set are shown in Table 3.
Additional files
Additional file 1: Information sheet and consent form (v3.0 06.09.17).
Information sheet provided to participants before study participation and
consent form to be completed by all enrolled participants. (PDF 454 kb)
Additional file 2: THRIVE baseline questionnaire (v1.5 15.11.13).
Questionnaire completed by study participants at the baseline visit
(12–24 weeks gestation) (PDF 5336 kb)
Additional file 3: THRIVE follow-up questionnaire (v2.1 25.01.16).
Questionnaire completed by study participants at the follow-up visit (6
months postnatal). (PDF 2561 kb)
Additional file 4: Standard protocol items: recommendations for
interventional trials (SPIRIT) checklist. SPIRIT checklist indicating the
location of relevant information with this publication. (DOC 121 kb)
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